Apnea is a known adverse effect of PGE used for infants with congenital heart disease. Some physicians prophylactically intubate infants on PGE before transporting them to tertiary referral centers.
I
N 1981 THE Food and Drug Administration approved prostaglandin E 1 (PGE 1 ) for use in neonates with congenital heart defects (CHDs). PGE 1 dilates the ductus arteriosus, which can provide pulmonary or systemic blood flow to infants with ductal-dependent lesions. [1] [2] [3] [4] [5] [6] As new surgical techniques improve the prognosis for a range of CHD, the early use of PGE 1 has become widespread before transport to regional medical centers for definitive care. PGE 1 infusion, however, has been associated with serious adverse effects, including apnea, hypotension, and fever. 7, 8 Concern for apnea and the technical difficulties securing a definitive airway during transport has lead to the common practice of elective intubation for infants receiving PGE 1 before transport. 9, 10 Endotracheal intubation, however, carries its own risks and may add to the potential for adverse events during transport, such as endotracheal tube occlusion, displacement, and equipment failure. [10] [11] [12] [13] [14] [15] Few studies have examined the complications associated with interhospital transport of infants receiving PGE 1 , and no standard of care for the preparation of these infants currently exists. We hypothesized that stable infants could safely be transported without endotracheal intubation. Therefore, we sought to describe the pretransport management of infants receiving PGE 1 infusions and to compare the transport complications of unintubated and electively intubated infants.
PATIENTS AND METHODS
We conducted a retrospective review of the medical charts of infants transported to Children's Hospital of Los Angeles with a diagnosis of CHD from January of 2000 to December of 2005. Subjects were included if they were transported by the Children's Hospital Emergency Transport Team and received PGE 1 during transport. This study was approved by the institutional review board at Children's Hospital of Los Angeles.
The Children's Hospital Emergency Transport Team is composed of staff physicians, registered nurses, respiratory therapists, and paramedics. All of the transport triage decisions are made by the physician, who determines the staffing needs and mode of transport for each call. Decisions regarding mode of transport are based on estimated travel time given distance, traffic, and weather conditions, as well as availability of fixed or rotor wing aircraft, rather than illness severity. Given the diversity of medical needs, no formal written protocols are used, and individual patient management strategies are at the discretion of the treating providers, although consultation with subspecialists (including cardiology and neonatology) is often sought before transport dispatch.
Demographic variables that were included in the analysis included gender, race/ethnicity (white, Hispanic, black, Asian, or other), estimated gestational age, and birth weight. Subjects were determined to have underlying pulmonary disease if they had airspace or pleural disease on chest radiograph or were described as having infant respiratory distress syndrome in the medical chart. Comorbid medical conditions such as sepsis, chromosomal abnormalities, and multiple congenital anomalies were also recorded. CHDs were categorized as 1-or 2-ventricle physiology based on the surgical repair planned or performed during the subsequent hospitalization. PGE 1 -related adverse effects and transport complications were the primary outcomes for this study. PGE 1 adverse effects were identified from previous studies 7, 8 and included apnea, hypoventilation, hypotension, arrhythmias, vasodilation, and fever. These adverse effects were categorized as likely if they were directly attributed to PGE 1 in the medical chart or if they occurred within 12 hours of starting PGE 1 without alternate medical explanations. Adverse effects were categorized as possible if they met the same criteria, but alternate medical explanations were identified for the observed adverse effect (eg, apnea in a premature infant).
Transport complications were defined as an acute change in cardiovascular, respiratory, or neurologic status. These complications included the following: (1) cardiovascular: arrhythmias and hypotension (defined as less than the fifth percentile for age); (2) respiratory: apnea (Ͼ20 seconds for any age), hypoventilation (respiratory rate Ͻ 20 or PCO 2 Ͼ 70 if arterial blood gas was obtained), desaturation (Ͼ10% drop from baseline saturation), pneumothorax, and endotracheal tube occlusion/displacement; and (3) neurologic: seizure activity, agitation (subjectively determined by transport team), and temperature instability (a change in core temperature outside of the reference range defined as 35.6°C to 37.5°C, requiring external warming or cooling). Complications requiring more than tactile stimulation, sedation, or a change in ambient isolette temperature were classified as major. Those that resolved without intervention or with tactile stimulation or sedation were classified as minor. Fever (temperature Ͼ 38.0°C) and hypothermia (temperature Ͻ36.5°C) were also considered minor complications.
Characteristics of PGE 1 infusion included route of administration (peripheral intravenous, umbilical artery catheter, umbilical vein catheter, or other central line), dose (Ͻ0.05, 0.05, or Ͼ0.05 g/kg per minute), and duration of infusion before transport (Ͻ3, 3-6, 6 -12, or Ͼ12 hours). Data regarding pretransport airway management included whether patients were intubated, place of intubation (delivery room, nursery, NICU, emergency department, ambulance/helicopter/airplane, or cardiothoracic ICU at the receiving facility), indication for intubation (Apgar score, apnea, hypoxia/cyanosis, hypotension, acidosis, respiratory distress, "for transport," "starting PGE 1 ," or "other"), and time of intubation (before or after starting PGE 1 ). Patients were subsequently classified as "unintubated," "electively intubated" (physiologically stable infants intubated for transport or starting PGE 1 ), or "emergently intubated."
Data were analyzed by using SPSS 14.0 (SPSS Inc, Chicago, IL). We calculated descriptive statistics for patient characteristics, pretransport management, PGE 1 adverse effects, and transport complications. Bivariate analyses ( 2 tests and Fisher's exact tests) and multivariate logistic regression were used to evaluate associations between major transport complications and patient characteristics, pretransport management variables, transport mode, and time. Variables were included in the multivariate regression if they had at least marginal bivariate significance in our data (P Ͻ .10) or had been identified as relevant in research published previously. Missing values varied for each item but in all of the cases were Ͻ5% and were not imputed. Percentages reported represent the valid percentage for each item. For all of the statistical tests, a 2-tailed P value of Ͻ.05 was considered statistically significant.
RESULTS
The characteristics of the study population are described in Table 1 . The mean gestational age was 38 weeks (range: 24 -40 weeks), and the median birth weight was 3100 g (range: 725-4636 g). The most common cardiac defect was hypoplastic left heart syndrome (25%), followed by transposition of the great arteries (19%) and coarctation of the aorta (15%). Table 2 describes the pretransport management of subjects. PGE 1 was started by the referring facility in 95% of cases at a median dose of 0.05 g/kg per minute (range: 0.01-0.42 g/kg per minute). Infusion occurred through a peripheral intravenous route in 70% of subjects and through an umbilical venous catheter route in 22%. A total of 129 infants (64%) were intubated before transport: 69 (34%) emergently before PGE 1 , 28 (14%) emergently after starting PGE 1 , and 23 (11%) electively. In 6 patients, the relationship between intubation and PGE 1 was unclear, and for another 3 it was uncertain whether the intubation was emergent or elective.
Adverse Effects of PGE 1 Probable PGE 1 adverse effects were noted in 74 subjects (38%), with an additional 16 (8%) classified as possible. Of probable and possible adverse effects combined, apnea was the most common (18%), followed by hypotension (13%) and fever (11%). Excluding fever, 32% of possible PGE 1 adverse effects occurred during transport, including 4 cases of apnea (2%). PGE 1 adverse effects and their relation to transport are described in Table 3 . 
Transport Complications
Complications occurred in 133 transports (66%). Major complications occurred during 84 transports (42%), with a total of 92 events in 75 patients (some transports and patients had multiple complications). These were roughly divided between respiratory (54%) and cardiovascular (46%) complications. Four intubated infants required airway interventions during transport: 3 were reintubated (1 for apnea and absent chest rise with bag valve mask and 2 for unintended extubation), and 1 had the endotracheal tube repositioned for asymmetric breath sounds. Table 4 lists the major transport complications and their management according to intubation status. Minor complications consisted of hypothermia in 55 patients (28%) and fever in 29 (14%). In addition, 3 cases of apnea and 2 of hypoventilation resolved with tactile stimulation, and 1 episode of agitation was treated with sedation. Bivariate predictors of major transport complications included intubation status (unintubated: 10%; electively intubated: 61%; emergently intubated: 52%; P Ͻ .01), PGE 1 dose (Ͻ0.05 g/kg per minute: 17%; 0.05 g/kg per minute: 44%; Ͼ0.05 g/kg per minute: 45%; P Ͻ .01), estimated gestational age (Ͻ32 weeks: 83%; 32-35 weeks: 45%; 36 -39 weeks: 23%; and Ͼ40 weeks: 47%; P Ͻ .01), mode of transport (ground: 35%; helicopter: 52%; fixed wing: 19%; P ϭ .03), comorbid medical conditions (49% with and 30% without; P Ͻ .01), and underlying pulmonary disease (55% with and 33% without; P ϭ .04). Results of the multivariate analysis are presented in Table 5 .
Subgroup Analysis
Subjects who were electively intubated for transport did not differ significantly from those who were not intubated with regard to race, gender, birth weight, type of CHD, or comorbid medical conditions. Compared with unintubated subjects, those who were electively intubated received a higher dose of PGE 1 (35% vs 12% received Ͼ0.05 g/kg per minute; P ϭ .05) and were transported by helicopter more often (50% vs 10%; P Ͻ .01). After controlling for these differences in a multi- Likely, n (%) Possible, n (%) Likely, n (%) Possible, n (%) Likely, n (%) Possible, n (%) In a separate analysis of the same sample, Lewis et al 7 described the adverse effects of therapy with PGE 1 and found cardiovascular and respiratory adverse effects in 32% and 31% of the sample, respectively, including apnea in 12%. Infants weighing Ͻ2 kg were at increased risk for respiratory depression, although potential confounding with prematurity was not addressed. 7 This and other early trials commonly used intra-arterial infusions of PGE 1 at the manufacturer-recommended dose of 0.1 g/kg per minute, and because successful surgical techniques for the palliation of hypoplastic left heart syndrome did not exist, infants with this condition were excluded. 4, 8, 17, 18 Although our sample included 25% with hypoplastic left heart syndrome, used a lower mean dose of PGE 1 , and had Ͻ5% with intra-arterial infusions, the overall incidence of adverse effects was similar. Probable adverse effects of PGE 1 were noted in 38% of subjects, with an 18% incidence of apnea overall. Overall, we found that comorbid medical conditions and higher PGE 1 dose were associated with possible PGE 1 adverse effects, whereas birth weight and gestational age were not independently associated with increased risk. Although several studies have described the transport of infants with CHD, 9, 10, 15, [19] [20] [21] we are unaware of any that have evaluated the incidence of PGE 1 adverse effects during transport. Apnea possibly related to PGE 1 occurred before transport in 24 (71%) of 34 patients, with 4 episodes during transport (2%). Three of these cases were managed with bag-valve-mask ventilation, and 1 required reintubation. We found infants with singleventricle physiology and a shorter interval between initiation of PGE 1 infusion and transport to be associated with an increased risk for adverse effects during transport.
The fear of PGE 1 -related apnea and potential challenges of securing a definitive airway during transport have lead to a variety of pretransport stabilization practices. No standard of care, particularly with regard to pretransport airway management, currently exists. In their review of the transport issues of infants on PGE 1 , Grubbs and Kraft summarize one approach, stating "the possibility of sudden onset apnea requires team members to be prepared to perform an emergency intubation . . . therefore, it is preferable in most instances for infants to be intubated before transport." 22 However, Yeager et al 10 voiced the counterargument that, "elective intubation exposes the infant to the potential for mechanical malfunction such as ventilator failure or tube plugging," and found that some transport teams did not routinely elect to intubate patients if they were otherwise stable. Several groups have described the potential for physiologic deterioration during transport, and scoring systems have been developed to help quantify the adverse impact of transport on critically ill infants and children. 23, 24 Few studies, however, have examined the specific transport risks of infants with CHD. HellstromWestas et al 21 published a descriptive study of the longdistance transport experience in Sweden during a 4-year period. In 286 transports, they reported 2 cases of blocked endotracheal tube, 3 additional "technical equipment failures," and 1 death. Only 16% of their sample, however, was intubated during transport, and less than one third (32%) received PGE 1 en route.
More recently, Yeager et al 10 reported the pretransport and post-transport characteristics and outcomes of neonates admitted to a regional cardiac ICU in New England. The authors used physiologic parameters of temperature, pH, and oxygen saturation before and after transport to characterize the stability of transported neonates with CHD. The authors describe a 17% incidence of transport-related physiologic deterioration; however, no analysis of infants receiving PGE 1 is reported, and no mention of airway management or specific interventions is made. Although our study identified a 42% rate of major transport complications, it is difficult to make direct comparisons given the differing operational definitions between studies.
The only published study to address the transport airway management of infants receiving PGE 1 was a 10-year retrospective review of the Australian transport experience by Browning Carmo et al. 15 The authors of that study reported that 78 of 300 infants receiving PGE 1 during transport were unintubated (26%), whereas 125 (42%) were electively intubated. Of the unintubated transported infants, only 2 developed apnea. In our study, 73 infants (36%) were unintubated during transport, and 23 (11%) were electively intubated for transport. None of the unintubated infants required intubation during transport for apnea.
We are unaware of any other studies that attempt to compare the transport complications of unintubated and electively intubated infants receiving PGE 1 . In our subgroup analysis, we found only 2 differences between these groups: infants who were electively intubated for transport received higher doses of PGE 1 than their unintubated counterparts and were more likely to be transported by helicopter. We controlled for these differences in our subgroup analysis and found that elective intubation remained the strongest independent predictor of major transport complications.
Although higher doses of PGE 1 were associated with more complications in our study, the effect of mode of transport on complications is less clear. Mode of transport was not independently associated with transport complications in multivariate analysis, and complication rates for helicopter transport were intermediate between ground and fixed-wing transport. The mode of transport was determined at triage by the team physician and was based on distance, traffic, and weather conditions rather than illness severity. Interestingly, transport time was not correlated with either transport mode or major complications.
There are several important limitations to our study. As with previous studies, ours was a retrospective cohort study limiting our ability to draw conclusions between cause and effect. Although we used conservative definitions for elective intubation and attempted to control for potential confounders between groups, only randomization could address whether elective intubation or unintubated transport is safer. We felt that the lack of published data made a randomized, prospective study unethical; however, with the combined results of this and the report of Browning Carmo et al, 15 prospective evaluation might be considered in the future. Although our overall sample size was large, only 11% were electively intubated, which limits the power of comparisons between groups.
Finally, our operational definition of transport complications was based on the need for interventions, rather than standardized physiologic parameters or scoring systems. Although we felt that the information obtained in this way was more meaningful when planning for appropriate staffing and equipment needs for transport, the inclusion of desaturation as a transport complication must be interpreted cautiously. All of the infants in this study received prostaglandin for congenital heart disease, which includes cyanotic lesions associated with varying degrees of desaturation, and for some lesions (eg, mixing defects and hypoplastic left heart syndrome) an oxygen saturation in the 70s or 80s is expected or even preferred. In general, a Ͼ10% decrease from baseline oxygen saturation was treated with an increase in FIO 2 ; however, the decision to intervene was left to the discretion of the treating transport staff and was not standardized in this retrospective review.
CONCLUSIONS
Despite high rates of PGE 1 adverse effects, elective intubation of infants for transport significantly increased the odds of a major transport complication. The risks of prophylactic intubation before the transport of otherwise stable infants on PGE 1 must be weighed carefully against possible benefits.
